JP2016501020A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501020A5 JP2016501020A5 JP2015544499A JP2015544499A JP2016501020A5 JP 2016501020 A5 JP2016501020 A5 JP 2016501020A5 JP 2015544499 A JP2015544499 A JP 2015544499A JP 2015544499 A JP2015544499 A JP 2015544499A JP 2016501020 A5 JP2016501020 A5 JP 2016501020A5
- Authority
- JP
- Japan
- Prior art keywords
- segment
- seq
- virus
- influenza
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 49
- 241000712431 Influenza A virus Species 0.000 claims description 41
- 210000004027 cell Anatomy 0.000 claims description 29
- 235000001014 amino acid Nutrition 0.000 claims description 28
- 229940024606 amino acid Drugs 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 28
- 241000700605 Viruses Species 0.000 claims description 26
- 206010022000 influenza Diseases 0.000 claims description 24
- 241000712461 unidentified influenza virus Species 0.000 claims description 19
- 229960005486 vaccine Drugs 0.000 claims description 17
- 208000037797 influenza A Diseases 0.000 claims description 9
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 8
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 8
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
- 239000004472 Lysine Substances 0.000 claims description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 8
- 229960001230 asparagine Drugs 0.000 claims description 8
- 235000009582 asparagine Nutrition 0.000 claims description 8
- 235000003704 aspartic acid Nutrition 0.000 claims description 8
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 8
- 108091034135 Vault RNA Proteins 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 210000003501 vero cell Anatomy 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 210000000991 chicken egg Anatomy 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 210000002845 virion Anatomy 0.000 claims description 2
- 239000000277 virosome Substances 0.000 claims description 2
- 229940126581 whole-virion vaccine Drugs 0.000 claims description 2
- 241000894007 species Species 0.000 claims 1
- 241000702620 H-1 parvovirus Species 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261732809P | 2012-12-03 | 2012-12-03 | |
| US61/732,809 | 2012-12-03 | ||
| PCT/EP2013/075294 WO2014086732A2 (en) | 2012-12-03 | 2013-12-02 | Influenza virus reassortment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501020A JP2016501020A (ja) | 2016-01-18 |
| JP2016501020A5 true JP2016501020A5 (OSRAM) | 2017-01-19 |
| JP6421128B2 JP6421128B2 (ja) | 2018-11-07 |
Family
ID=49713076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015544499A Active JP6421128B2 (ja) | 2012-12-03 | 2013-12-02 | リアソータントインフルエンザａウイルス |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9708585B2 (OSRAM) |
| EP (1) | EP2925356A2 (OSRAM) |
| JP (1) | JP6421128B2 (OSRAM) |
| KR (1) | KR20150110494A (OSRAM) |
| CN (1) | CN105120893B (OSRAM) |
| AU (2) | AU2013354219A1 (OSRAM) |
| BR (1) | BR112015012380A2 (OSRAM) |
| CA (1) | CA2893429A1 (OSRAM) |
| HK (1) | HK1214959A1 (OSRAM) |
| MX (1) | MX2015006927A (OSRAM) |
| WO (1) | WO2014086732A2 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20150110494A (ko) * | 2012-12-03 | 2015-10-02 | 노파르티스 아게 | 재배열 인플루엔자 a 바이러스 |
| US10323231B2 (en) * | 2015-04-24 | 2019-06-18 | University Of Rochester | Attenuated influenza vaccines and uses thereof |
| KR20180035807A (ko) | 2015-06-26 | 2018-04-06 | 세퀴러스 유케이 리미티드 | 항원적으로 매치된 인플루엔자 백신 |
| GB201602535D0 (en) * | 2016-02-12 | 2016-03-30 | Univ Edinburgh | Improved flu vaccine yield |
| WO2019044636A1 (ja) * | 2017-08-28 | 2019-03-07 | 一般財団法人阪大微生物病研究会 | リアソータントインフルエンザウイルスの段階的作出方法 |
| ES2991988T3 (es) | 2017-10-30 | 2024-12-05 | Takeda Pharmaceuticals Co | Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica |
| WO2020051766A1 (zh) * | 2018-09-11 | 2020-03-19 | 上海市公共卫生临床中心 | 一种广谱抗流感疫苗免疫原及其应用 |
| KR101954904B1 (ko) | 2018-10-15 | 2019-03-06 | 남종규 | 복층의 태양광 설치 구조 |
| CN111647610B (zh) * | 2020-06-02 | 2021-09-03 | 扬州大学 | 一种互换ha和ns1缺失基因包装信号的h9n2亚型禽流感病毒及其构建方法和应用 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| US6468544B1 (en) | 1998-06-12 | 2002-10-22 | Mount Sinai School Of Medicine Of The City University Of New York | Interferon inducing genetically engineered attenuated viruses |
| MXPA02003069A (es) | 1999-09-24 | 2002-09-30 | Smithkline Beecham Biolog | Vacuna intranasal contra el virus de la influenza.. |
| WO2001064846A1 (fr) | 2000-03-03 | 2001-09-07 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Cellule utilisable pour culture sans serum et culture en suspension, et procede de production de virus pour vaccin utilisant cette cellule |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| AR032575A1 (es) | 2001-02-23 | 2003-11-12 | Smithkline Beecham Biolog | Uso de una preparacion antigenica de gripe para la fabricacion de una vacuna intradermica de la gripe y estuche farmaceutico que comprende dicha vacuna |
| ATE503493T1 (de) | 2001-02-23 | 2011-04-15 | Glaxosmithkline Biolog Sa | Influenza vakzinzusammensetzungen zur intradermaler verabreichung |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| BRPI0509606B1 (pt) | 2004-04-05 | 2019-01-15 | Pah Usa 15 Llc | emulsões de óleo-em-água microfluidizadas e composições para vacinas |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| US20080254067A1 (en) | 2004-05-20 | 2008-10-16 | Id Biomedical Corporation | Process for the Production of an Influenza Vaccine |
| DK2368975T3 (en) | 2004-12-23 | 2015-01-05 | Medimmune Llc | Non-tumorigenic MDCK cell line for the propagation of viruses |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| CA2613284A1 (en) | 2005-06-21 | 2007-01-04 | Medimmune Vaccines, Inc. | Methods and compositions for expressing negative-sense viral rna in canine cells |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| SI1951296T2 (sl) | 2005-11-01 | 2014-09-30 | Novartis Vaccines And Diagnostics Gmbh | Iz celic izpeljana virusna cepiva z nizko stopnjo preostale celiäśne dna z obdelavo z betapropiolaktonom |
| NZ568210A (en) | 2005-11-04 | 2012-12-21 | Novartis Vaccines & Diagnostic | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| US9254318B2 (en) * | 2006-03-31 | 2016-02-09 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
| RU2457250C2 (ru) | 2006-04-19 | 2012-07-27 | Медиммуне, Ллк | Способы и композиции для экспрессии антисмысловой вирусной рнк в клетках собаки |
| WO2008043774A1 (en) | 2006-10-12 | 2008-04-17 | Glaxosmithkline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
| AU2007330494B2 (en) | 2006-12-06 | 2014-03-13 | Seqirus UK Limited | Vaccines including antigen from four strains of influenza virus |
| US8778847B2 (en) * | 2007-06-13 | 2014-07-15 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Immunogenic peptides of influenza virus |
| EP2045323A1 (en) | 2007-10-05 | 2009-04-08 | Avir Green Hills Biotechnology Research Development Trade Ag | Linear expression constructs for production of influenza virus particles |
| CN107365751B (zh) * | 2008-12-16 | 2021-07-09 | 纳米医疗公司 | 流感疫苗的生产 |
| EP2233152A1 (en) * | 2009-03-24 | 2010-09-29 | Avir Green Hills Biotechnology Research Development Trade Ag | High growth reassortant influenza A virus |
| EA021009B1 (ru) | 2009-05-21 | 2015-03-31 | Новартис Аг | ОБРАТНАЯ ГЕНЕТИКА С ИСПОЛЬЗОВАНИЕМ НЕЭНДОГЕННЫХ ПРОМОТОРОВ pol I |
| KR20120101318A (ko) * | 2009-06-25 | 2012-09-13 | 메디뮨 엘엘씨 | 돼지 인플루엔자 헤마글루티닌 변이체 |
| JP2013500712A (ja) | 2009-07-31 | 2013-01-10 | ノバルティス アーゲー | 逆遺伝学系 |
| CA2800150C (en) | 2010-05-21 | 2018-09-04 | Novartis Ag | Influenza virus reassortment method |
| FR2962739B1 (fr) * | 2010-07-13 | 2014-01-31 | Univ Claude Bernard Lyon | Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza |
| KR20150110494A (ko) * | 2012-12-03 | 2015-10-02 | 노파르티스 아게 | 재배열 인플루엔자 a 바이러스 |
-
2013
- 2013-12-02 KR KR1020157016758A patent/KR20150110494A/ko not_active Ceased
- 2013-12-02 WO PCT/EP2013/075294 patent/WO2014086732A2/en not_active Ceased
- 2013-12-02 CA CA2893429A patent/CA2893429A1/en not_active Abandoned
- 2013-12-02 AU AU2013354219A patent/AU2013354219A1/en not_active Abandoned
- 2013-12-02 CN CN201380071503.1A patent/CN105120893B/zh active Active
- 2013-12-02 MX MX2015006927A patent/MX2015006927A/es unknown
- 2013-12-02 JP JP2015544499A patent/JP6421128B2/ja active Active
- 2013-12-02 US US14/648,886 patent/US9708585B2/en active Active
- 2013-12-02 HK HK16102968.6A patent/HK1214959A1/zh unknown
- 2013-12-02 EP EP13799527.0A patent/EP2925356A2/en not_active Withdrawn
- 2013-12-02 BR BR112015012380A patent/BR112015012380A2/pt not_active IP Right Cessation
-
2017
- 2017-06-13 US US15/621,270 patent/US10500266B2/en active Active
-
2018
- 2018-09-19 AU AU2018232956A patent/AU2018232956B2/en active Active
-
2019
- 2019-10-28 US US16/665,104 patent/US20200155666A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016501020A5 (OSRAM) | ||
| JP2016509864A5 (OSRAM) | ||
| JP2015119730A5 (OSRAM) | ||
| Milián et al. | Current and emerging cell culture manufacturing technologies for influenza vaccines | |
| Thomas et al. | Cell-mediated protection in influenza infection | |
| Ping et al. | Development of high-yield influenza A virus vaccine viruses | |
| Zhou et al. | Characterization of uncultivable bat influenza virus using a replicative synthetic virus | |
| Horimoto et al. | Enhanced growth of seed viruses for H5N1 influenza vaccines | |
| Chen et al. | The impact of key amino acid substitutions in the hemagglutinin of influenza A (H3N2) viruses on vaccine production and antibody response | |
| Feng et al. | Equine and canine influenza H3N8 viruses show minimal biological differences despite phylogenetic divergence | |
| JP2012511914A5 (OSRAM) | ||
| Petiot et al. | Influenza viruses production: evaluation of a novel avian cell line DuckCelt®-T17 | |
| JP2013179943A5 (OSRAM) | ||
| WO2008156681A2 (en) | Adenoviral vectors for influenza virus production | |
| Neumann et al. | Identification of amino acid changes that may have been critical for the genesis of A (H7N9) influenza viruses | |
| Li et al. | Screening of the high yield influenza B virus on MDCK cell and cloning of its whole genome | |
| Van Wielink et al. | Adaptation of a Madin–Darby canine kidney cell line to suspension growth in serum-free media and comparison of its ability to produce avian influenza virus to Vero and BHK21 cell lines | |
| Abdoli et al. | Comparison between MDCK and MDCK-SIAT1 cell lines as preferred host for cell culture-based influenza vaccine production | |
| Johnson et al. | Identification of influenza A/PR/8/34 donor viruses imparting high hemagglutinin yields to candidate vaccine viruses in eggs | |
| Mostafa et al. | Efficient generation of recombinant influenza a viruses employing a new approach to overcome the genetic instability of HA segments | |
| Silva et al. | Recent advances and current challenges in process intensification of cell culture‐based influenza virus vaccine manufacturing | |
| Barman et al. | Manipulation of neuraminidase packaging signals and hemagglutinin residues improves the growth of A/Anhui/1/2013 (H7N9) influenza vaccine virus yield in eggs | |
| Koudstaal et al. | Suitability of PER. C6® cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics | |
| Merten et al. | Virus production under suspension conditions | |
| Medina et al. | Vero/CHOK1, a novel mixture of cell lines that is optimal for the rescue of influenza A vaccine seeds |